FRI-236 - Safety and efficacy of Ombitasvir, Paritaprevir/Ritonavir and Dasabuvir with or without ribavirin in chronic hepatitis C patients receiving opioid substitution therapy: a pooled analysis across 12 clinical trials

Autor: Grebley, J., Puoti, M., Wedemeyer, H., Cooper, C., Sulkowski, M.S., Foster, G., Berg, T., Villa, E., Rodriguez-Perez, F., Wyles, D.L., Alami, N.N., Zhang, Z., Dumas, E., Dore, G.J.
Zdroj: In Journal of Hepatology 2017 66(1) Supplement:S514-S514
Databáze: ScienceDirect
Externí odkaz: